Literature DB >> 3931283

Reactivity of factor VIII inhibitors in a micro ELISA for factor VIII: CAg and in solid phase immunoisolation of VIII: CAg.

O Nordfang, M Ezban, B Dinesen.   

Abstract

Factor VIII coagulant antigen (VIII: CAg) was measured in a sandwich-ELISA. Microplates were used as solid phase and peroxidase conjugated F(ab')2 fragments of IgG isolated from inhibitor plasma was used as label without affinity purification. The capacity of the assay was high and the sensitivity for VIII: CAg was 0.002 U/ml. Using this assay it was possible to measure coagulation inactive VIII: CAg in samples from purification studies. Below 0.05 VIII: CAg U/ml these samples responded in parallel with standard plasma. Seven of 7 inhibitor antibodies tested were able to inhibit binding of peroxidase-conjugate in the VIII: CAg assay, and the inhibitory capacity correlated with coagulation inhibition as measured by the Bethesda method. Using the highest titered antibodies bound to a solid phase, VIII: CAg was isolated and identified in SDS-PAGE as a doublet with a molecular weight of 77-80 kD.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3931283

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  3 in total

1.  Expression of a cytomegalovirus IE-1-factor VIII cDNA hybrid gene in transgenic mice.

Authors:  T R Mikkelsen; B Chapman; N Din; J Ingerslev; P Kristensen; K Poulsen; J P Hjorth
Journal:  Transgenic Res       Date:  1992-07       Impact factor: 2.788

2.  Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells.

Authors:  B S Chapman; R M Thayer; K A Vincent; N L Haigwood
Journal:  Nucleic Acids Res       Date:  1991-07-25       Impact factor: 16.971

3.  Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain.

Authors:  P A Foster; C A Fulcher; R A Houghten; S de Graaf Mahoney; T S Zimmerman
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.